NCT02912169

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal in Patients With Alzheimer's Disease

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Ageless Regenerative Institute · Industry
• Sex: All
• Age: 55 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with Alzheimer's Disease and clinical outcomes?

Detailed description

Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF) will be infused intra-venous and Intra nasal. The therapy is composed of cells derived from a patients' own adipose tissue that are isolated within approximately 1 hour and immediately delivered back to the patient.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
PROCEDURE	Liposuction under local anesthesia	Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
BIOLOGICAL	Infusion of AD-SVF via IV and Intranasal	IV and Intranasal Infusion of isolated AD-SVF

Timeline

• Start date: 2015-11-01
• Primary completion: 2017-11-15
• Completion: 2017-11-15
• First posted: 2016-09-23
• Last updated: 2017-11-24

Locations

1 site across 1 country: United States